No Data
No Data
No Data
No Data
No Data
Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Treatment of Myotubular and Centronuclear Myopathies
STRASBOURG, Pa., Jan. 6, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S.
PR NewswireJan 7, 2022 05:12
Dynacure to Present at 40th Annual J.P. Morgan Healthcare Conference
STRASBOURG, France and PHILADELPHIA, Jan. 3, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating and life-threatening genetic diseases, today anno
PR NewswireJan 4, 2022 05:10
Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku
STRASBOURG, France and PHILADELPHIA and KYOTO, Nov. 10, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of pa
PR NewswireNov 10, 2021 16:16
US stock IPO | Shopping center REIT PECO, Italian pharmaceutical glass container manufacturer STVN listed this week
The IPOs that received a lot of attention this week include shopping mall REIT Phillips Edison and pharmaceutical glass container manufacturer Stevanato, which are expected to raise up to 527 million US dollars and 960 million US dollars respectively.
富途資訊Jul 13, 2021 17:38 · IPO
No Data
No Data